Evidence map›Paper›PMID 33809063›Full record

ArticleCancers2021

Single-Cell Expression Landscape of SARS-CoV-2 Receptor

Guangchun Han, Ansam Sinjab, Kieko Hara, Warapen Treekitkarnmongkol, Patrick Brennan, Kyle Chang, Elena Bogatenkova, Beatriz Sanchez-Espiridion, Carmen Behrens, Luisa M Solis and 21 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 6 institutions in 1 country.

Guangchun HanDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ansam SinjabDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Kieko HaraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Warapen TreekitkarnmongkolDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-7542-5201
Patrick BrennanPathology Department, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Kyle ChangGuardant Health, Redwood City, CA 94063, USA.
Elena BogatenkovaPathology Department, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Beatriz Sanchez-EspiridionDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Carmen BehrensDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Luisa M SolisDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Boning GaoHamon Center for Therapeutic Oncology Research, University of Texas Southwestern, Dallas, TX 75390, USA.
Luc GirardHamon Center for Therapeutic Oncology Research, University of Texas Southwestern, Dallas, TX 75390, USA.
Jianjun ZhangDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Boris SepesiDepartment of Cardiovascular and Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77005, USA.
Tina CasconeDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lauren A ByersDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Don L GibbonsDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jichao ChenDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Seyed Javad MoghaddamDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-5350-307X
Edwin J OstrinDepartment of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-4538-6539
Paul ScheetDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA.
Junya FujimotoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jerry ShayDepartment of Cell Biology, University of Texas Southwestern, Dallas, TX 75390, USA.ORCID 0000-0001-5052-0627
John V HeymachDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
John D MinnaHamon Center for Therapeutic Oncology Research, University of Texas Southwestern, Dallas, TX 75390, USA.
Steven DubinettDepartment of Medicine, The University of California Los Angeles, Los Angeles, CA 90095, USA.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Christopher S StevensonLung Cancer Initiative at Johnson and Johnson, Cambridge, MA 02142, USA.
Avrum E SpiraLung Cancer Initiative at Johnson and Johnson, Cambridge, MA 02142, USA.
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Humam KadaraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USThe University of Texas Southwestern Medical Center · USBoston University · USGuardant (United States) · USJohnson & Johnson (United States) · USUniversity of California, Los Angeles · US

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
Transcriptional and epigenetic basis of lung epithelial cell fateR01HL153511 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, JICHAO · 2020 to 2023
$2.5M
NCI NIH HHS P50 CA070907NCI NIH HHS P50CA070907NHLBI NIH HHS R01 HL153511NIH HHS 1S10OD024977
6 · The paper itself

Abstract

The novel coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Severely symptomatic COVID-19 is associated with lung inflammation, pneumonia, and respiratory failure, thereby raising concerns of elevated risk of COVID-19-associated mortality among lung cancer patients. Angiotensin-converting enzyme 2 (ACE2) is the major receptor for SARS-CoV-2 entry into lung cells. The single-cell expression landscape of

Indexed as

alveolar epithelial cellsCOVID-19lung neoplasmssingle-cell RNA sequencing

Identifiers

PMID33809063
PMCPMC7998226
OpenAlexW3136025082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.